Hypertrophic Cardiomyopathy Epidemiology Forecast Insight

DelveInsight’s ‘Hypertrophic Cardiomyopathy–Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Hypertrophic Cardiomyopathy, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Hypertrophic Cardiomyopathy Disease Understanding

Hypertrophic Cardiomyopathy (HCM) is a common genetically inherited heart disease and represents an important cause of cardiovascular morbidity and mortality in patients of all ages. HCM is characterized by left ventricular hypertrophy unexplained by secondary causes and a non-dilated left ventricle with preserved or increased ejection fraction. It is commonly asymmetrical, with the most severe hypertrophy involving the basal interventricular septum

 

The histological features of HCM include myocyte hypertrophy and disarray, as well as interstitial fibrosis. Hypertrophy is also frequently associated with left ventricular diastolic dysfunction. In the majority of patients, HCM has a relatively benign course. However, HCM is also an important cause of sudden cardiac death, particularly in adolescents and young adults. Non-sustained ventricular tachycardia, syncope, a family history of sudden cardiac death, and severe cardiac hypertrophy are major risk factors for sudden cardiac death. This complication can usually be averted by the implantation of a cardioverter-defibrillator in high-risk patients. In addition, atrial fibrillation (AF) is also a common complication and is not well tolerated.

 

The diagnosis of HCM is based predominantly on echocardiographic variables, including dynamic LVOTO, LVH, distribution of increased muscle thickness, mechanism and severity of MR, and degree of diastolic dysfunction. Current indications for surgical intervention include symptomatic patients refractory to medical therapy who can tolerate the risk of surgery and patients with marked outflow gradients, even if asymptomatic. The routine applications of genetic testing and preclinical identification of family members represent an important advance. The genetic discoveries have enhanced understanding of the molecular pathogenesis of HCM and have stimulated efforts designed to identify new therapeutic agents.

 

Pharmacologic therapy remains the cornerstone of treatment for alleviating HCM symptoms, including using β-adrenergic receptor blocker to blunt the heart rate, increase diastolic filling time, restore cardiac filling pressure and attenuate exercise. Disopyramide may be added to reduce symptoms in patients with LVOTO via its negative inotropic effect

Hypertrophic Cardiomyopathy Epidemiology

The Hypertrophic Cardiomyopathy epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Hypertrophic Cardiomyopathy epidemiology segmented as the Prevalence of Hypertrophic Cardiomyopathy, Gender-specific Prevalence of Hypertrophic Cardiomyopathy, and Type-specific Prevalence of Hypertrophic Cardiomyopathy. The report includes the Prevalent scenario of Hypertrophic Cardiomyopathy in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Hypertrophic Cardiomyopathy Epidemiology

The epidemiology segment also provides the Hypertrophic Cardiomyopathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The total prevalent population of Hypertrophic Cardiomyopathy associated in 7MM countries was estimated to be 227,354 cases in 2020 and expected to increase at a CAGR of 2.70% for the study period, i.e., 2018–2030.
  • As per the estimates, United States has the highest prevalent population of Hypertrophic Cardiomyopathy in 7MM.
  • Among the EU5 countries, Germany had the highest prevalent population of Hypertrophic Cardiomyopathy. On the other hand, Japan had the lowest number of cases, 3,997 cases in 2020.

Scope of the Report

  • Hypertrophic Cardiomyopathy report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Hypertrophic Cardiomyopathy Epidemiology Report and Model provide an overview of the risk factors and global trends of Hypertrophic Cardiomyopathy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Hypertrophic Cardiomyopathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Hypertrophic Cardiomyopathy
  • The report provides the segmentation of the Hypertrophic Cardiomyopathy epidemiology by prevalent Cases of Hypertrophic Cardiomyopathy in 7MM
  • The report provides the segmentation of the Hypertrophic Cardiomyopathy epidemiology by Prevalence of Hypertrophic Cardiomyopathy, Prevalence of Hypertrophic Cardiomyopathy based on Etiology specific factors, Age-specific cases of Hypertrophic Cardiomyopathy in 7MM

Report Highlights

  • 10-year Forecast of Hypertrophic Cardiomyopathy  epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Hypertrophic Cardiomyopathy
  • Prevalent Cases of Hypertrophic Cardiomyopathy based on Etiology-specific Factors
  • Gender-specific Prevalence of Hypertrophic Cardiomyopathy

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Hypertrophic Cardiomyopathy?
  • What are the key Findings of Hypertrophic Cardiomyopathy epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021–2030)?
  • What would be the total number of patients with Hypertrophic Cardiomyopathy across the 7MM during the forecast period (2021–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021–2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021–2030)?
  • What are the disease risk, burden, and unmet needs of Hypertrophic Cardiomyopathy?
  • What are the currently available treatments for Hypertrophic Cardiomyopathy?

Reasons to buy

The Hypertrophic Cardiomyopathy Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Hypertrophic Cardiomyopathy  market
  • Quantify patient populations in the global Hypertrophic Cardiomyopathy market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hypertrophic Cardiomyopathy therapeutics in each of the markets covered
  • Understand the magnitude of Hypertrophic Cardiomyopathy population by its prevalent cases
  • Understand the magnitude of Hypertrophic Cardiomyopathy population by its clinical manifestation specific cases
  • The Hypertrophic Cardiomyopathy epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Hypertrophic Cardiomyopathy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Hypertrophic Cardiomyopathy Market Overview at a Glance

3.1. Market Share (%) Distribution of Hypertrophic Cardiomyopathy in 2018

3.2. Market Share (%) Distribution of Hypertrophic Cardiomyopathy in 2030

4. Executive Summary of Hypertrophic Cardiomyopathy

5. Disease Background and Overview

5.1. Introduction

5.2. Risk Factors

5.3. Symptoms

5.4. Types of HCM

5.5. Molecular Genetics basis

5.6. Pathophysiology

5.6.1. Cardiac abnormalities

5.6.2. Genetic abnormalities

5.7. Disease Stages and Progression

5.7.1. Stages of HCM

5.7.2. Clinical progression of HCM

5.8. Manifestations

5.9. Clinical workup

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Diagnosed Patient Population of HCM

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Prevalent Cases of Hypertrophic Cardiomyopathy in the United States

6.4.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in the United States

6.4.3. Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United States

6.4.4. Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Prevalent Cases of Hypertrophic Cardiomyopathy in Germany

6.5.1.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in Germany

6.5.1.3. Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Germany

6.5.1.4. Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in Germany

6.5.2. France

6.5.2.1. Prevalent Cases of Hypertrophic Cardiomyopathy in France

6.5.2.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in France

6.5.2.3. Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in France

6.5.2.4. Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in France

6.5.3. Italy

6.5.3.1. Prevalent Cases of Hypertrophic Cardiomyopathy in Italy

6.5.3.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in Italy

6.5.3.3. Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Italy

6.5.3.4. Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Italy

6.5.4. Spain

6.5.4.1. Prevalent Cases of Hypertrophic Cardiomyopathy in Spain

6.5.4.2. Diagnosed cases of Hypertrophic Cardiomyopathy in Spain

6.5.4.3. Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Spain

6.5.4.4. Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Spain

6.5.5. United Kingdom

6.5.5.1. Prevalent Cases of Hypertrophic Cardiomyopathy in the United Kingdom

6.5.5.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom

6.5.5.3. Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom

6.5.5.4. Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom

6.6. Japan

6.6.1. Prevalent Cases of Hypertrophic Cardiomyopathy in Japan

6.6.2. Diagnosed Cases of Hypertrophic Cardiomyopathy in Japan

6.6.3. Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in Japan

6.6.4. Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in Japan

7. Treatment and Management

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Table

Table 1: Summary of Hypertrophic cardiomyopathy, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Diagnosed Patient Population of Hypertrophic Cardiomyopathy in 7MM (2018–2030)

Table 3: Prevalent Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Table 4: Diagnosed Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Table 5: Gender-specific diagnosed Cases Hypertrophic Cardiomyopathy in the United States (2018–2030)

Table 6: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Table 7: Prevalent Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Table 8: Diagnosed Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Table 9: Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Table 10: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Table 11: Prevalent Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Table 12: Diagnosed Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Table 13: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Table 14: Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Table 15: Prevalent Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Table 16: Diagnosed Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Table 17: Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Table 18: Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Table 19: Prevalent Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Table 20: Diagnosed Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Table 21: Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Table 22: Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Table 23: Prevalent Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Table 24: Diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Table 25: Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Table 26: Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in United Kingdom (2018–2030)

Table 27: Prevalent Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Table 28: Diagnosed Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Table 29: Gender-specific diagnosed cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Table 30: Type-specific diagnosed cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

List of Figures

Figure 1: Schematic representation of two possible sites of obstructive HCM. (A) Sub-aortic obstructive HCM (B) Mid-ventricular obstructive HCM

Figure 2: Locations of genes within the cardiac sarcomere known to cause hypertrophic cardiomyopathy

Figure 3: The ECS Recommended Standardized Diagnosis Work-up for HCM

Figure 4: Diagnosed Patient Population of Hypertrophic Cardiomyopathy in 7MM (2018–2030)

Figure 5: Prevalent Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Figure 6: Diagnosed Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Figure 7: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Figure 8: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United States (2018–2030)

Figure 9: Prevalent Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Figure 10: Diagnosed Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Figure 11: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Figure 12: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Germany (2018–2030)

Figure 13: Prevalent Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Figure 14: Diagnosed Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Figure 15: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Figure 16: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in France (2018–2030)

Figure 17: Prevalent Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Figure 18: Diagnosed Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Figure 19: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Figure 20: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Italy (2018–2030)

Figure 21: Prevalent Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Figure 22: Diagnosed Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Figure 23: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Figure 24: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Spain (2018–2030)

Figure 25: Prevalent Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Figure 26: Diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Figure 27: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Figure 28: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in the United Kingdom (2018–2030)

Figure 29: Prevalent Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Figure 30: Diagnosed Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Figure 31: Gender-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Figure 32: Type-specific diagnosed Cases of Hypertrophic Cardiomyopathy in Japan (2018–2030)

Figure 33: A stepwise approach to the clinical management of patients diagnosed with hypertrophic cardiomyopathy

Forward to Friend

Need A Quote